Clinical Overview

“Decreased QT Interval” is the source dataset’s own telegraphic label for a QT interval that measures abnormally short. The term a clinician writes is a short QT interval, or QT shortening, which is what this page is titled and scoped to. The QT interval, measured from the onset of the QRS complex to the end of the T wave, represents the combined duration of ventricular depolarization and repolarization (Sattar and Chhabra, StatPearls Electrocardiogram, 2023; Burns and Buttner, LITFL QT Interval, 2024) — the same interval QT prolongation measures, read at its opposite extreme.

The distinction that matters most here mirrors the one this project’s QT Prolongation page draws, in the opposite direction. QT shortening is an ECG finding — a measurement produced, far more often than not, by something acting on an otherwise ordinary heart: hypercalcemia, digoxin, hyperkalemia, acidosis, hyperthermia, or simply a fast heart rate (Sattar and Chhabra, 2023; Burns and Buttner, LITFL QT Interval, 2024). Short QT Syndrome (SQTS) is a separate, specific diagnosis — a rare, autosomal dominant inherited channelopathy first described in 2000, caused by mutations that make ventricular repolarization abnormally fast, that carries a genuine risk of atrial fibrillation, ventricular fibrillation, and sudden cardiac death (Burns and Buttner, LITFL Short QT Syndrome, 2025; Pérez-Riera et al., Journal of Electrocardiology, 2024). Every patient with the syndrome has the finding; a short QT interval reported on a monitor strip does not, by itself, mean the patient has the syndrome. The dataset’s “SQT” label denotes the measurement, not a diagnosis, and nothing about a record carrying it implies an inherited disease is present.

The mechanism is accelerated repolarization, the mirror image of QT prolongation’s delayed repolarization. In congenital SQTS, gain-of-function mutations in myocardial potassium channels increase outward potassium efflux, producing markedly short QT intervals — genotypes labeled SQT1 through SQT3 are associated with QTc values under roughly 300-320 ms in every reported patient. A separate mechanism, loss-of-function mutations in the L-type cardiac calcium channel that reduce calcium influx during the action potential’s plateau phase, produces a more modest shortening — genotypes SQT4 and SQT5, with QTc under roughly 360 ms in every reported patient (Burns and Buttner, LITFL Short QT Syndrome, 2025). Both routes shorten the atrial and ventricular refractory periods and increase transmural dispersion of repolarization — different layers of the ventricular wall repolarizing at different rates — which is the substrate for reentrant arrhythmia, explaining why SQTS produces both atrial fibrillation and life-threatening ventricular arrhythmias rather than one or the other (Burns and Buttner, LITFL Short QT Syndrome, 2025). Inheritance is autosomal dominant, and a 2024 review focused on the condition’s electrocardiographic features documents nine genotypes described to date, more than the classic ion-channel set alone (Pérez-Riera et al., 2024).

Acquired short QT arrives at the same “too fast” endpoint through different, non-genetic routes. Hypercalcemia accelerates the plateau phase of the ventricular action potential, producing marked QT shortening — one reported case showed a QTc of 260 ms (Burns and Buttner, LITFL Hypercalcaemia, 2024). Digoxin shortens atrial and ventricular refractory periods as part of its normal pharmacologic effect, alongside a characteristic pattern of ST-segment depression (Burns, LITFL Digoxin Effect, 2024). And because the raw QT interval lengthens as heart rate slows and shortens as it rises, tachycardia itself shortens the measured QT — the same rate dependence that makes QT correction formulas necessary in the first place (Burns and Buttner, LITFL QT Interval, 2024).

Clinical significance differs sharply depending on which of these is in play. In congenital SQTS, cardiac arrest is the most common initial presentation, reported in roughly one-third of cases, and atrial fibrillation has been documented in about 80% of reported cases (Burns and Buttner, LITFL Short QT Syndrome, 2025). A 2026 case report describes SQTS first presenting as apparently “lone” atrial fibrillation in a 66-year-old with a QTc of 335 ms, whose rhythm deteriorated into polymorphic ventricular tachycardia requiring multiple defibrillations before quinidine controlled it and an ICD was implanted (Yoo et al., JACC Case Reports, 2026). Reported age at presentation for the congenital form spans from infancy to the sixth decade of life, with a median around 30 years, and the true prevalence of the disease is unknown (Burns and Buttner, LITFL Short QT Syndrome, 2025). Acquired short QT from hypercalcemia, digoxin, or a fast heart rate does not carry this same inherited arrhythmic burden on its own — it functions mainly as a marker of its cause — but severe hypercalcemia has itself been associated with ventricular irritability and VF arrest, so an extremely short interval should never be waved off as a benign artifact (Burns and Buttner, LITFL Hypercalcaemia, 2024).

The finding itself is frequently silent. Many acquired cases produce no symptoms referable to the QT interval at all; the patient’s presentation, if any, is driven by the underlying cause (hypercalcemia, digoxin dosing) rather than by the interval. In congenital SQTS, reported symptoms include syncope (in about 24% of reported cases) and palpitations (up to about 31%), with cardiac arrest as the presenting event in roughly a third — meaning a substantial share of patients have no preceding symptom at all before a first, potentially fatal, arrhythmic event (Burns and Buttner, LITFL Short QT Syndrome, 2025).

Causes and risk factors divide the same way. Acquired causes include hypercalcemia, hyperkalemia, acidosis, hyperthermia, digoxin, and a fast heart rate (Sattar and Chhabra, StatPearls Electrocardiogram, 2023; Burns and Buttner, LITFL QT Interval, 2024). Congenital SQTS is caused by potassium-channel gain-of-function mutations (SQT1-3) or calcium-channel loss-of-function mutations (SQT4-5), inherited in an autosomal dominant pattern (Burns and Buttner, LITFL Short QT Syndrome, 2025). Recognized risk factors that should raise suspicion for the syndrome specifically, rather than an incidental short reading, include a family history of short QT interval or unexplained sudden cardiac death, and new “lone” atrial fibrillation in a relatively young patient without structural heart disease (Burns and Buttner, LITFL Short QT Syndrome, 2025; Yoo et al., 2026).

Interpretation Guide

Key Features:

• Rate: not a defining feature in itself, but an input to the measurement — the raw QT shortens as the rate rises, mirroring how it lengthens as the rate falls. Always record the heart rate a QT measurement was taken at, and treat a short QT found at a fast rate with the same rate-correction scrutiny given to a long QT found at a slow one (Burns and Buttner, LITFL QT Interval, 2024)
• Rhythm: not a defining feature of the measurement itself, but worth flagging in the other direction — new-onset atrial fibrillation has been documented in roughly 80% of congenital SQTS patients, and a strip showing both a short QT and atrial fibrillation in an otherwise healthy patient is a combination worth a second look rather than two unrelated findings (Burns and Buttner, LITFL Short QT Syndrome, 2025; Yoo et al., 2026)
• P waves: not part of the QT measurement and not a defining feature of this finding
• PR interval: within normal limits unless a separate, coexisting conduction abnormality is present, with one notable exception — digoxin’s vagal effect can prolong the PR interval (up to roughly 240 ms) on the same strip as its characteristic QT shortening and ST depression (Burns, LITFL Digoxin Effect, 2024)
• QRS complex: not a defining feature; the QT is measured from QRS onset as with any QT assessment, so QRS duration and morphology do not themselves indicate a short interval
• ST segment: a genuinely distinguishing feature between causes. Congenital SQTS characteristically shows a short, or entirely absent, ST segment, with the T wave taking off almost directly from the QRS (Burns and Buttner, LITFL Short QT Syndrome, 2025). Digoxin effect, by contrast, produces a distinctive downsloping “reverse tick” or “Salvador Dali” ST depression alongside its QT-shortening effect — a different-looking ST segment for a similar QT-interval change (Burns, LITFL Digoxin Effect, 2024)
• T waves: tall, narrow, symmetrically peaked T waves, particularly prominent in the precordial leads, are characteristic of congenital SQTS — the same morphology that predisposes implanted defibrillators to T-wave oversensing and inappropriate shocks in these patients (Burns and Buttner, LITFL Short QT Syndrome, 2025). A 2024 review focused specifically on the syndrome’s electrocardiographic features also describes an asymmetric “minus-plus” (biphasic) T-wave sign and other T-wave morphology clues detectable on vectorcardiography (Pérez-Riera et al., 2024). Digoxin effect instead produces a biphasic T wave whose initial negative deflection connects smoothly with the depressed ST segment, most visible in leads with a dominant R wave (Burns, LITFL Digoxin Effect, 2024)
• QT interval: the defining feature. General reference sources describe a QT/QTc under about 360 ms as short (Sattar and Chhabra, StatPearls Electrocardiogram, 2023), with LITFL’s QT interval page describing values under about 350 ms as abnormally short and reporting a case of marked shortening to 260 ms with hypercalcemia (Burns and Buttner, LITFL QT Interval, 2024). For the congenital syndrome specifically, LITFL’s Short QT Syndrome page states that a QTc under 330 ms in men or under 340 ms in women should be considered diagnostic on its own, with a higher threshold of under 360 ms in men or under 370 ms in women considered diagnostic when supported by symptoms or family history — and separately describes genotype-specific ranges, with SQT1-3 patients all measuring under roughly 300-320 ms and SQT4-5 patients all measuring under roughly 360 ms (Burns and Buttner, LITFL Short QT Syndrome, 2025). [CLINICAL REVIEW NEEDED: the source does not state how its general diagnostic threshold and its genotype-specific ranges relate to one another, or which a reader should default to without knowing the genetic subtype. Treat any single short-QT cutoff as an approximate flag for further evaluation rather than a diagnostic line on its own, and expect that a QTc in the high-300s-to-mid-300s range does not rule the syndrome out on the strength of a threshold alone.]
• Other findings: in extreme hypercalcemia, Osborn (J) waves — notching of the terminal QRS, best seen in lead V1 — can accompany the short QT interval, and severe cases have been associated with ventricular irritability and VF arrest (Burns and Buttner, LITFL Hypercalcaemia, 2024). Prominent U waves can accompany digoxin effect (Burns, LITFL Digoxin Effect, 2024)

Key Leads

• Lead II or V5 – The same default leads standard QT-measurement guidance names generally, useful here as a starting point for isolating a clean QRS onset and T-wave end (Burns and Buttner, LITFL QT Interval, 2024)
• Precordial leads (V1-V3) – Where congenital SQTS’s tall, narrow, peaked T waves are most apparent, and where Osborn waves from severe hypercalcemia are best seen (Burns and Buttner, LITFL Short QT Syndrome, 2025; Burns and Buttner, LITFL Hypercalcaemia, 2024)
• Leads with a dominant R wave (V4-V6) – Where digoxin’s characteristic biphasic T wave and downsloping ST depression are most visible, useful for distinguishing a digoxin-shortened QT from the congenital syndrome’s picture (Burns, LITFL Digoxin Effect, 2024)
• Whichever lead gives the clearest QRS-onset-to-T-wave-end view – Not a fixed lead but the operative rule: measure several successive beats in the cleanest available lead rather than eyeballing a single complex, the same standard technique used for any QT assessment (Burns and Buttner, LITFL QT Interval, 2024)

Differential Diagnosis

• QT Prolongation (QTIE) — the opposite-direction finding on the same measurement. Distinguishing clue: confirm which side of normal the corrected value actually falls on before reasoning about either one — a QTc measured at a fast rate can look deceptively short on the raw tracing without correction, and vice versa at a slow rate.
• Sinus Tachycardia (ST) — the rate explanation. Distinguishing clue: the raw QT shortens as the rate rises, so an apparently short absolute QT at 130 bpm may correct to an entirely normal QTc once rate-adjusted; report the correction formula used before calling an interval abnormally short at a fast heart rate.
• Atrial Fibrillation (AFIB) — the rhythm that can be the first sign something is wrong, not an unrelated coincidence. Distinguishing clue: new “lone” atrial fibrillation in an otherwise healthy, relatively young patient, on a strip that also shows a short QTc, is the exact combination a 2026 case report describes as an underrecognized presentation of Short QT Syndrome — check the QT before filing new AF in a young patient as idiopathic.
• ST Depression (STDD) — the accompanying finding that points toward a specific acquired cause rather than the congenital syndrome. Distinguishing clue: a shortened QT paired with downsloping, “reverse tick”-shaped ST depression and a biphasic T wave in the lateral precordial leads is the digoxin-effect pattern, not SQTS — check the medication list before escalating for genetic evaluation.

Treatment Brief

The interval itself is not treated by a monitoring technician or nursing student. What is owned here is measuring it correctly, recognizing which accompanying findings point to an acquired cause versus a reason for concern about the congenital syndrome, and knowing when to escalate.

• Report the QT, the heart rate it was measured at, and the correction formula used, the same discipline used for a long QT — a short interval reported without its rate is not interpretable by the next reader (Burns and Buttner, LITFL QT Interval, 2024).
• Check the obvious acquired causes before treating a short QT as unexplained: recent digoxin, serum calcium, potassium, temperature, and acid-base status. Digoxin’s shortened QT comes with a distinctive downsloping ST depression and biphasic T wave, and hypercalcemia’s comes with a possible Osborn wave at extreme levels — both are clues to the underlying cause, not incidental findings (Burns, LITFL Digoxin Effect, 2024; Burns and Buttner, LITFL Hypercalcaemia, 2024).
• Remember that digoxin effect on the ECG is not, by itself, a marker of digoxin toxicity — a shortened QT and reverse-tick ST depression in a patient on digoxin is an expected pharmacologic signature, not automatically an alarm (Burns, LITFL Digoxin Effect, 2024).
• Do not dismiss an extremely short QT as an artifact. Severe hypercalcemia has been associated with ventricular irritability and VF arrest, and it warrants the same urgency as any other electrolyte-driven repolarization abnormality (Burns and Buttner, LITFL Hypercalcaemia, 2024).
• Escalate for cardiology evaluation when a short QT is not explained by an obvious acquired cause — particularly in a younger patient with a personal or family history of unexplained syncope, sudden cardiac death, or “lone” atrial fibrillation. Congenital SQTS has documented cardiac arrest as its first presentation in roughly a third of cases, and lone AF has been reported as its opening sign (Burns and Buttner, LITFL Short QT Syndrome, 2025; Yoo et al., 2026).
• Long-term management of the congenital syndrome is a different conversation from managing an acquired finding, and belongs with the diagnosis rather than the tracing: the 2022 ESC guidelines’ short-QT-syndrome-specific recommendations include genetic testing in the diagnostic workup, quinidine as the pharmacologic agent of choice, and implantable cardioverter-defibrillator placement for higher-risk patients (Zeppenfeld et al., 2022 ESC Guidelines, European Heart Journal, 2022; Burns and Buttner, LITFL Short QT Syndrome, 2025).
• Know that SQTS patients with an ICD carry a specific device-management issue worth flagging to the team rather than managing directly: the same tall, narrow T waves that define the syndrome predispose to T-wave oversensing and inappropriate shocks (Burns and Buttner, LITFL Short QT Syndrome, 2025).
• Compare against a prior ECG when one exists. A short QT that has been stable for years in an asymptomatic patient reads very differently from one that is new.